Most Read Articles
19 Jun 2019
Acquired immunodeficiency syndrome (AIDS) remains as one of the world’s leading causes of mortality in global public health. Dr Charles Hicks shared his insights into the increasing role of dolutegravir (DTG; Tivicay, GSK) – an integrase strand transfer inhibitor (INSTI) – in HIV therapy during the 4th National AIDS Conference 2018 at Swiss Garden International Hotel and Residences, Kuala Lumpur.
19 Jun 2019
The choice between nonvitamin K antagonist oral anticoagulants (NOACs) or vitamin K antagonists (VKAs) for stroke prevention appears to be complex and largely heterogenous across different, countries, a new study has found.
2 days ago
Monotherapy with tenofovir disoproxil fumarate increases virologic response for up to 240 weeks in pretreated patients with hepatitis B virus infection (HBV) who are resistant to entecavir and/or adefovir, a new study has found.
Elvira Manzano, 3 days ago
Long-term treatment with the interleukin-5 receptor alpha-directed cytolytic monoclonal antibody benralizumab led to long-term control of asthma, improvement in pulmonary function, and was safe in patients with severe eosinophilic asthma in the 2-year integrated analysis of the SIROCCO, CALIMA, and ZONDA pivotal studies plus the BORA extension study reported at ATS 2019.

Intensive BP treatment cardioprotective in T2DM patients receiving standard glycaemic control

07 Aug 2018

Intensive blood pressure (BP) treatment yields a significant reduction in the risk of cardiovascular events, including heart failure, in patients with type 2 diabetes mellitus (T2DM) receiving standard but not intensive glycaemic control therapy, as shown in a recent study.

The present analysis included T2DM patients (mean age 62.8 years; 48 percent female) enrolled in the ACCORD BP trial (Action to Control Cardiovascular Risk in Diabetes Blood Pressure). There were 2,362 patients receiving standard glucose-lowering therapy (standard BP treatment, n=1,178; intensive BP, n=1,184) and 2,371 on intensive glycaemic control treatment (standard BP, n=1,193; intensive BP, n=1,178).

During a mean follow-up of 4.5 years, the primary outcome of a composite of cardiovascular death, nonfatal myocardial infarction, nonfatal stroke and hospitalized congestive heart failure occurred in 528 patients overall. In the standard glycaemic control group, the risk of a cardiovascular event was significantly lower among patients receiving intensive vs standard BP therapy (hazard ratio [HR], 0.71; 95 percent CI, 0.56–0.90; p=0.005). In the intensive glycaemic control group, on the other hand, the risk did not significantly differ between the two BP treatment subgroups (HR, 1.06; 0.83–1.36; p=0.61).

Similar results were found for stroke risk, which was markedly lower among patients in the standard glycaemic control group receiving intensive BP treatment. Such risk reduction was absent in the intensive glycaemic control group.

A nonsignificant increase in all-cause mortality risk was seen among patients in the intensive glycaemic control group receiving intensive vs standard BP treatment (HR, 1.38; 0.99–1.92; p=0.05).

Researchers pointed out that the benefits of intensive BP treatment were observed only in ACCORD BP patients receiving standard glycaemic control without additional risk factors. Additional studies are warranted to confirm the safety and efficacy of intensive BP treatment in high-risk patients with T2DM.

Digital Edition
Asia's trusted medical magazine for healthcare professionals. Get your MIMS Doctor - Malaysia digital copy today!
Sign In To Download
Editor's Recommendations
Most Read Articles
19 Jun 2019
Acquired immunodeficiency syndrome (AIDS) remains as one of the world’s leading causes of mortality in global public health. Dr Charles Hicks shared his insights into the increasing role of dolutegravir (DTG; Tivicay, GSK) – an integrase strand transfer inhibitor (INSTI) – in HIV therapy during the 4th National AIDS Conference 2018 at Swiss Garden International Hotel and Residences, Kuala Lumpur.
19 Jun 2019
The choice between nonvitamin K antagonist oral anticoagulants (NOACs) or vitamin K antagonists (VKAs) for stroke prevention appears to be complex and largely heterogenous across different, countries, a new study has found.
2 days ago
Monotherapy with tenofovir disoproxil fumarate increases virologic response for up to 240 weeks in pretreated patients with hepatitis B virus infection (HBV) who are resistant to entecavir and/or adefovir, a new study has found.
Elvira Manzano, 3 days ago
Long-term treatment with the interleukin-5 receptor alpha-directed cytolytic monoclonal antibody benralizumab led to long-term control of asthma, improvement in pulmonary function, and was safe in patients with severe eosinophilic asthma in the 2-year integrated analysis of the SIROCCO, CALIMA, and ZONDA pivotal studies plus the BORA extension study reported at ATS 2019.